U.S. exports of polypeptide, protein, and glycoprotein hormones and derivatives (nesoi) (HS 293719) totaled $475.5M in August 2026.
Importers of Polypeptide, Protein, and Glycoprotein Hormones and Derivatives (NESOI) paid $528K in duties in August 2026, an effective tariff rate of 0.36% of the $145.7M imported — duty actually collected as a share of that value, not the published tariff schedule. Polypeptide, Protein, and Glycoprotein Hormones and Derivatives (NESOI) imports of $145.7M in August 2026 ran 21% above the year-to-date monthly average of $120.5M.
Last updated: August 2026 dataPolypeptide, protein, and glycoprotein hormones not elsewhere specified — including gonadotropins, thyrotropin, erythropoietin, and related recombinant biologics — are classified under tariff line 2937190000. These are among the most complex pharmaceutical imports from a regulatory standpoint: many are approved biologics subject to FDA's Center for Biologics Evaluation and Research (CBER) or Center for Drug Evaluation and Research (CDER) oversight, and biosimilar versions face additional interchangeability determinations. The NESOI designation means importers should confirm that a more specific heading does not apply before using this line.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
223 shipments/mo
The NESOI rule requires that 293719 be used only when no more specific heading applies. Somatotropin and its analogues belong under 293711; insulin and its salts under 293712. All other polypeptide, protein, and glycoprotein hormones — such as gonadotropins, erythropoietin, or thyrotropin — fall under 2937190000. When a novel biologic's classification is uncertain, a binding ruling request to CBP is the most reliable approach.
No — HTS classification is based on the chemical nature of the product, not its regulatory approval status. A biosimilar erythropoietin and the reference biologic both classify under 2937190000. However, biosimilar status is highly relevant to FDA admissibility: the product must reference an approved biosimilar application, and interchangeability designations affect substitution rights in the US market.
HSChapter 29
Trade Directory
List your company under HS 293719 — Polypeptide, Protein, and Glycoprotein Hormones and Derivatives (NESOI), so the companies trading it can find you. Be the first supplier listed.
Subheading 1 of 9 in heading 2937
Subheading 293719 · $475.5M of $509.3M
ImportsExports
Imports
$145.7MYoY · free account
Exports
$475.5MYoY · free account
12-mo low · imports
YoY · free accountOver the twelve months to August 2026, the U.S. imported $14.9B of Polypeptide, Protein, and Glycoprotein Hormones and Derivatives (NESOI).
Through August 2026. Source: U.S. Census Bureau.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Import Value | Effective Tariff % | Dutiable Share | Duty Collected |
|---|---|---|---|---|---|
| 2937190000 | Polypeptide, Protein & Glycoprotein Hormones,NESOI | $145.7M | 0.36% | 3.37% | $528K |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 2937190000 | Polypeptide, Protein & Glycoprotein Hormones,NESOI | $475.5M |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.
Exports · August 2026
destination
Germany and Italy together take 86% of it.
customs district
origin
entry
rate provision · imports
96.6% enters free of duty; duty collected equals 0.36% of total import value.